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We reviewed the records of 66 patients who underwent cardiopulmonary
bypass; half of these patients received the plasmin inhibitor, tranexamic acid.
The demographics were not different between the group who received tranex-
amic acid and the group who did not (control group). There was no difference
in the heparin or protamine requirements between the two groups. There was a
significantly greater amount of 12-hr chest tube bleeding in the control group
(495 ± 484 vs. 863 ± 655 in the control and tranexamic acid groups, respec-
tively; p < .02). There was no difference between the groups in either the post-
operative hematocrit, platelet count or the number ofpatients requiring transfu-
sion. Although tranexamic acid decreased the amountofchest tube output, there
was no demonstrable patient benefit derived from its use.
INTRODUCTION
Cardiopulmonary Bypass (CPB)d can be complicated by significant post-operative
bleeding. CPB frequently induces a low-grade fibrinolytic state, which lasts several hours
postoperatively. Despite full heparin anticoagulation on CPB, thrombin activity during
CPB may not be completely inhibited, and fibrinolysis may result [1]. A method recently
introduced at our institution in an attempt to decrease postoperative bleeding in cardiac
surgery patients is the use of a plasmin inhibitor, tranexamic acid (TA). Preventing fibri-
nolysis and platelet activation during CPB may improve hemostatic function postopera-
tively. TA, which is a trans isomer of4-aminoethylcyclohexane carboxylic acid, has an in
vitro half-life of80min and is 95 percentrenally excreted [2]. Itexerts its effectby attach-
ing to the high-affinity binding sites ofplasminogen and plasmin with a resultant block-
ade offibrin lysis.
When TAbecame introduced to our clinical practice, it was instituted as a "routine"
part of our care. We therefore had the opportunity to investigate whether TA affected
heparin requirements, bleeding, or transfusion requirements in patients undergoing CPB.
To determine these issues, records were reviewed for aperiod oftime before and after the
use ofTA became a standard part of our anesthetic care.
METHODS
Following Institutional Review Board approval, the charts from 33 patients who
received TA and from 33 patients who did not receive TA (control group, non-TA) were
reviewed. All patients underwent either coronary artery bypass grafting or a single valve
replacement. Patients in the TAgroup received 10 gm ofintravenous TA over a 1-hr peri-
od; the infusion was started immediately after anesthetic induction and completed before
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initiation of CPB. Heparin requirements (total, per patient weight and per patient weight
per time of CPB) were evaluated. The activated clotting time (ACT) was maintained
greater than 600 sec throughout the time of CPB. The amount of protamine required to
return the ACT to baseline and measured heparin concentration to zero was also record-
ed. The platelet count prior to CPB, 1 hr following CPB and the next morning were com-
pared between the two groups. Bleeding during the time of CPB was suctioned with the
use ofa pump suction apparatus, and following protamine neutralization ofheparin, with
a cell-saver device. Chest tube output every hr for the first 12-hr period, blood transfused
in the operating room and the blood transfused in the intensive care unit were also record-
ed. As per our usual protocol, chest tube drainage was auto transfused to all patients. Data
are presented as mean ± SD.Analysis was performed with two tail t-Test; p < .05 was con-
sidered statistically significant.
RESULTS
There was no difference between the TAand control groups with respect to age, sex,
height, weight or duration ofCPB.
See Table 1 for a tabular display ofthe results. The duration ofCPB was 135 ± 65 in
the TA group and 132 ± 48 in the control group (p = NS). The heparin dose was 54,682 ±
22,486 units (u) and 48,545 ± 16,175 u in the TA and non-TA groups, respectively (p =
NS).
The amountofheparin perbody weightpertime ofCPB (u/kg/min) was 5.5 ± 2.1 and
5.1 ± 2.0 in the TA and control groups, respectively (p = NS). The dose ofprotamine nec-
essary to achieve adequate heparin neutralization was 338 ± 102 mg and 311 ± 50 mg in
the TA and control groups, respectively (p = NS). Twelve-hr chest tube drainage was 495
± 484 ml and 863 ± 655 ml in the TA and control groups, respectively (p < .02) (See
Figure 1). Average blood transfusion requirements were 0.7 ± 1.8 u in the TAgroup (eight
of33 patients, 24percent) and0.6 ± 1.3 u in thecontrol group (nine of33 patients, 27 per-
cent) (p = NS). There was no significant relationship between the duration ofCPB and the
amountofchesttube output. The hematocrit levels on the morning following surgery were
not significantly different between the two groups (27 ± 5 percent vs. 26 ± 3 percent in
the TA and control groups, respectively).
There was no significant difference between the groups with respect to initial platelet
count (255,000 ± 101,000 vs. 228,000 ± 48,000 in the TA and control groups, respective-
ly) or in the platelet count the morning following surgery (122,000 ± 50,000 vs. 115,000
±39,000in theTAandcontrol groups, respectively). Theplatelet count 1 hrfollowing dis-
continuation ofCPB (126,000 ± 49,000 vs. 101,000 ± 34,000 in the tranexamic acid and
control groups, respectively) likewise was not significantly different, although a trend
towards a higher platelet count was evident in the group who received TA (p < .06).
Table 1. The characteristics ofthe patients in the control and tranexamic acid groups.
Chest tube Hematocrit Platelet count
Group CPBa (min) Heparin (u) Protamine (mg) output (ml) (next day) (next day)
Control 132+48 48,545+16,175 311+50 863+655 26+3 115,000±34,000
TAb 135+65 54,682+22,486 338+±102 495+484 27+5 122,000_50,000
acardiopulmonary bypass duration;btranexamic acid.
Results areexpressed as mean + SD. The chest tube output represents the output for the first twelve postop-
erative hr. The only significant difference between the first two groups was in the chest tube output.







Control Group Trenexamic Acid Group
Figure 1. The 12-hr chest tube output in the patients in the control group (in gray) and the
tranexamic acid group (striped). The shaded area represents the 25th to 75th percentiles, and the
dark line represents the median.
DISCUSSION
Fibrinogen, which is synthesized in the liver, is cleaved by thrombin to form fibrin
monomers. Factor XIIIa cross-links the fibrin monomers stabilizing the fibrin mesh.
Plasminogen normally binds to fibrinogen prior to its conversion to fibrin. Physiological
cleavage of plasminogen to plasmin only occurs on the surface of fibrin. Plasmin splits
fibrin into peptide fragments (i.e., fibrin split products). Fibrinolysis inhibitors bind to
plasminogen and plasmin, interfering with the ability to cleave fibrin. Fibrinolysis
inhibitors are contraindicated in disseminated intravascular coagulation because one
would not want to prevent lysis ofintravascular clots [3]. Antifibrinolytics have been suc-
cessfully utilized in patients undergoing cardiac surgery [1, 4, 5], prostate surgery [6],
head and neck surgery [7], liver transplantation [8], in cancer patients treated with cyto-
toxic agents [9] and in patients with subarachnoid hemorrhage [10]. CPB induces a fibri-
nolytic state as evidenced by an increase in fibrin split products, a decrease in plasmino-
gen and active formation offibrinopeptide A (a degradation product offibrinogen) [11].
As in previous studies [3, 4], TAsignificantly decreased the chest tube output but had
no effect on blood transfusion requirements. The routine use ofa device that allows auto-
transfusion of blood shed through the chest tube probably was responsible for the similar
transfusion requirements and similar postoperative hematocrit levels. This brings to light
the question of cost effectiveness: if antifibrinolytics do result in a decreased amount of
bleeding, but not a decreased need for transfusion, are they worth the price? At our insti-
tution, the hospital charge for the commonly used antifibrinolytics are as follows: TA (10
gm), $128; aprotinin (2,000,000 kallikrein inhibitor units), $300; epsilon aminocaproic
acid (1750 mg), $4. The patient charges for these medications are approximately four
times these costs. While these regimens are not necessarily therapeutically equivalent,
they do represent the clinical doses ofthe commonly-used antifibrinolytics. On the other
hand, the hospital acquisition cost for the chest tube drainage system is $66 for the basic
system and $83 for the autotransfusion system.
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TA is not without side effects. Some of the less serious side effects include nausea,
vomiting and diarrhea following oral administration and hypotension following rapid
intravenous injection. The more serious theoretical side effects include development of a
hypercoagulable state, which could cause thrombosis ofvasculargrafts orresult in throm-
boembolic events. Concern has been expressed about the potential of antifibrinolytics
causing thrombosis with resultant myocardial infarction in patients undergoing cardiac
surgery [1]. While these concerns are theoretical, in the absence of a clear benefit to
patients (i.e., a decreased need for transfusion, shorter time to hospital discharge, etc.), it
would seem prudent to avoid an expensive medication that may also have potentially sig-
nificant side-effects.
Heparin and protamine requirements were also examined in order to rule out any
alterations in bleeding due to an effect of TA on heparin or protamine requirements. TA
did not affect the heparin required to maintain the ACT > 600 or the amount ofprotamine
required to return theACT to baseline. Thus, the effect ofTA on the amount ofpostoper-
ative bleeding is not due to an effect on heparin or protamine requirements. Although the
platelet count tended to decrease less in the patients who received TA (p < .06), this was
not significantly different nor long-lasting, as the platelet counts the following morning
were very similar (p = .58). The clinical action ofTAis competitive inhibition ofplasmin
by blocking binding sites of fibrinogen and fibrin; whether it also blocks platelet recep-
tors is unknown. It is interesting to postulate, however, that a part of the mechanism for
the decrease in bleeding found in the TA group is a platelet-sparing effect.
In conclusion, tranexamic acid decreased chest tube bleeding in patients undergoing
cardiopulmonary bypass. This decrease was unaccompanied by a decreased need for
transfusion, or an increased postoperative hematocrit. Our data suggest that until such an
effect is shown, the routine use of TA (and perhaps of similar antifibrinolytic agents)
should be reevaluated in cases where autotransfusion of shed blood is practiced.
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